HYDROLYZED HYALURONIC ACID
What is HYDROLYZED HYALURONIC ACID (CAS N/A) in cosmetics and what are its global regulatory limits?
HYDROLYZED HYALURONIC ACID (CAS No. N/A) is a verified cosmetic ingredient primarily functioning as Hair Conditioning, Humectant, Skin Conditioning in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 0.05–0.1% within an optimal stability window of pH 4–8.
7-Track Official Regulatory Label Names Matrix
Primary Statutory Gazette Only · Zero Machine Translation| Jurisdiction Track | Official Statutory Label Name | One-Click Copy |
|---|---|---|
| 1. Korea (MFDS Standard Name) | HYDROLYZED HYALURONIC ACID (KR MFDS Registered) | |
| 2. Korea Former Nomenclature History | — | — |
| 3. European Union (EU CosIng Glossary) | HYDROLYZED HYALURONIC ACID | |
| 4. United States (US PCPC / MoCRA INCI) | HYDROLYZED HYALURONIC ACID | |
| 5. US FDA OTC Monograph Active Name | — (Cosmetic Inactive / Non-OTC) | — |
| 6. China (NMPA IECIC Standard Name) | 水解透明质酸 | |
| 7. Japan (JCIA Standard / MHLW Quasi-Drug) | 加水分解ヒアルロン酸 · [QD: 加水分解ヒアルロン酸] |
Layer 1 — Statutory Regulatory Limits Across 6 Regions
| Region | Status | Max Limit | Conditions & Statutory Source |
|---|---|---|---|
| Korea (MFDS) | Unregulated | GMP | Listed in official cosmetic inventory |
| Europe (EU) | Unregulated | GMP | Listed in official cosmetic inventory |
| United States (FDA) | Unregulated | GMP | Listed in official cosmetic inventory |
| China (NMPA) | Listed / Allowed | GMP | IECIC Entry #6353 |
| Japan (MHLW) | Unregulated | GMP | Listed in official cosmetic inventory |
| ASEAN (ACD) | Unregulated | GMP | Listed in official cosmetic inventory |
Layer 2 — Toxicological & Historical Safe Use Concentrations (CIR / SCCS / CN IECIC / IFRA)
“EU SCCS Safe Opinion Limit” is the toxicological safe threshold (MoS≥100), whereas “US CIR Reported Max Use” and “CN IECIC Historical Max Use” represent historical maximum concentrations in commercial products.
| Assessment Basis | Application Scope | Concentration Range | Verdict & Dossier Reference |
|---|---|---|---|
| CN IECIC Historical Max Use | leave_on | ≤ 2% | Safe (MoS≥100)NMPA IECIC (2025) Entry 06154 (2025) |
| CN IECIC Historical Max Use | rinse_off | ≤ 1.5% | Safe (MoS≥100)NMPA IECIC (2025) Entry 06154 (2025) |
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility
| Formulation Group | Min – Q1 – Median – Q3 – Max (%) | Role & Mechanism | Source ID |
|---|---|---|---|
| Group A — Aqueous Toner / Serum / Ampoule | 0.05% · 0.0625% · 0.1% · 0.1% · 0.1% | Aqueous serum, toner & hydrogel matrix formulation component | Global Starter Formulation Library Statistical Distribution (n=6, EVONIK 6) |
| Group B — O/W & W/O Emulsion / Lotion / Cream | 0.03% · 0.1% · 0.1% · 0.1% · 0.5% | Emulsion cream & lotion structural / conditioning agent | Global Starter Formulation Library Statistical Distribution (n=17, EVONIK 17) |
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Thermally stable up to 50°C during standard emulsification.
Cellular & Molecular Target Mechanism Flow
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.
Academic & Toxicological Synthesis
Tier 1 SynthesisSynthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.
Linked Peer-Reviewed Literature (NIH PubMed) (3)
Fabrication of High-Resolution Fine Microneedles Derived from Hydrolyzed Hyaluronic Acid Gels in Vacuum Environment Imprinting Using Water Permeable Mold [PMID: 36547309 · 2022]
Hydrolyzed hyaluronic acid high-resolution fine microneedles of 13 µm in diameter and 24 µm in height were fabricated from hydrolyzed hyaluronic acid gels made in mixtures of water using vacuum environment imprint lithography processes with a water permeable mold. The gas traps of water and volatile solvents in the imprint materials cause transfer failure in the conventional water impermeable molds of quartz and metal. However, the water permeable mold allows the use of 67 wt% dilution water with high solubility to increase the fluidity of the hydrolyzed hyaluronic acid during the patterning of high-resolution fine microneedles for cosmetics and pharmaceuticals. This demonstration sets a new paradigm of functional pure gels for high-resolution nano-patterning applications with various cosmetic and pharmaceutical materials containing dilution water using a water permeable mold.
Various methods to combine hyaluronic acid and antimicrobial peptides coatings and evaluation of their antibacterial behaviour [PMID: 31376454 · 2019]
To prevent bacterial adhesion and contamination, biomaterials exhibiting both antiadhesive and biocidal properties are the most promising way. However, control of the properties combination is not so easy due, in particular, to antagonist mechanisms. Antibacterial surfaces against Staphylococcus epidermidis adhesion were here elaborated by using both nisin grafting and repelling polysaccharide coating. We evaluated two strategies aiming to improve the antimicrobial peptide (AMP) immobilization parameters (i.e., the accessibility and/or local density) in order to obtain the best antimicrobial activity on surfaces. We thus (i) grafted the nisin on a surface previously coated with hydrolyzed hyaluronic acid (HA) (to decrease the length of the polysaccharide chains) or (ii) coupled nisin and HA in solution before grafting this complex on surfaces. XPS analysis pointed out a lower amount of nisin on the surface for both approaches compared to the immobilization of nisin on native HA. However, an antibacterial activity was maintained, probably due to a higher local density of the AMP when surfaces were modified with hydrolyzed hyaluronic acid, leading to a better combination of antiadhesive-biocidal properties. Microscopy fluorescent observations demonstrated that accumulation of dead cells was also avoided by some coatings architecture.
Inactivation of vaccinia virus by a diffusible component from hydrolyzed hyaluronic acid [PMID: 13076197 · 1953]
Frequently Asked Questions (AEO Position 0)
- Q1. What are the official 7-track regulatory label names for HYDROLYZED HYALURONIC ACID?
- Standard label names are US PCPC INCI: 'HYDROLYZED HYALURONIC ACID', EU CosIng: 'HYDROLYZED HYALURONIC ACID', KR MFDS: 'HYDROLYZED HYALURONIC ACID (KR MFDS Registered)', CN NMPA IECIC: '水解透明质酸', and JP JCIA: '加水分解ヒアルロン酸'.
- Q2. Is HYDROLYZED HYALURONIC ACID restricted or permitted in EU, US, KR, CN, and JP cosmetics?
- Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
- Q3. What is the typical formulation concentration and optimal pH window for HYDROLYZED HYALURONIC ACID?
- In aqueous_serum systems, HYDROLYZED HYALURONIC ACID is typically formulated between 0.05% and 0.1% (median 0.1%), with an optimal stability window of pH 4–8.
- Q4. What are the known formulation incompatibilities and synergy pairings for HYDROLYZED HYALURONIC ACID?
- Recommended synergy pairings include GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL. Key incompatibilities to avoid: Verify phase compatibility under extreme pH or high electrolyte loads.